Advertisement

Topics

EyeGate nets $9.3mm via FOPO

15:40 EDT 19 Jun 2017 | Elsevier Business Intelligence

Ophthalmic drug developer EyeGate Pharmaceuticals Inc. netted $9.3mm through a follow-on public offering of 5.34mm common sha...

Original Article: EyeGate nets $9.3mm via FOPO

NEXT ARTICLE

More From BioPortfolio on "EyeGate nets $9.3mm via FOPO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.